JP2013529080A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013529080A5 JP2013529080A5 JP2013510643A JP2013510643A JP2013529080A5 JP 2013529080 A5 JP2013529080 A5 JP 2013529080A5 JP 2013510643 A JP2013510643 A JP 2013510643A JP 2013510643 A JP2013510643 A JP 2013510643A JP 2013529080 A5 JP2013529080 A5 JP 2013529080A5
- Authority
- JP
- Japan
- Prior art keywords
- dom7h
- seq
- variant
- variable domain
- single variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000035772 mutation Effects 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 8
- 108060003951 Immunoglobulin Proteins 0.000 claims 8
- 102000018358 immunoglobulin Human genes 0.000 claims 8
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 6
- 108020001507 fusion proteins Proteins 0.000 claims 4
- 102000037865 fusion proteins Human genes 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- -1 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34651910P | 2010-05-20 | 2010-05-20 | |
| US61/346,519 | 2010-05-20 | ||
| PCT/EP2011/058298 WO2011144751A1 (en) | 2010-05-20 | 2011-05-20 | Improved anti-serum albumin binding variants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013529080A JP2013529080A (ja) | 2013-07-18 |
| JP2013529080A5 true JP2013529080A5 (cg-RX-API-DMAC7.html) | 2014-07-03 |
Family
ID=44352234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013510643A Pending JP2013529080A (ja) | 2010-05-20 | 2011-05-20 | 改良された抗血清アルブミン結合変異体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9040668B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2571900A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2013529080A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20130109977A (cg-RX-API-DMAC7.html) |
| CN (1) | CN103003303A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011254559B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112012029280A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2799633A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201291009A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL222802A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2012013406A (cg-RX-API-DMAC7.html) |
| SG (1) | SG185437A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011144751A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| CA2895875A1 (en) | 2012-12-21 | 2014-06-26 | Sanofi | Exendin-4 derivatives |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| PL3374392T3 (pl) * | 2015-11-13 | 2022-03-28 | Ablynx Nv | Ulepszone domeny zmienne immunoglobuliny wiążące albuminę surowicy |
| KR102533456B1 (ko) | 2016-05-18 | 2023-05-17 | 모더나티엑스, 인크. | 릴랙신을 인코딩하는 폴리뉴클레오타이드 |
| WO2024170756A1 (en) | 2023-02-17 | 2024-08-22 | Ablynx N.V. | Polypeptides binding to the neonatal fc receptor |
| WO2025021183A1 (zh) * | 2023-07-27 | 2025-01-30 | 上海复宏汉霖生物医药有限公司 | 编码促肾上腺皮质激素的多核苷酸及其相关组合物和方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| DK1517921T3 (da) | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| EP1737962B1 (en) | 2004-03-24 | 2010-09-01 | Domantis Limited | Gas1 universal leader |
| JP2008500830A (ja) | 2004-06-01 | 2008-01-17 | ドマンティス リミテッド | 増加した血清半減期を有する二重特異性融合抗体 |
| WO2006059106A2 (en) | 2004-12-02 | 2006-06-08 | Domantis Limited | Bispecific domain antibodies targeting serum albumin and glp-1 or pyy |
| WO2007085814A1 (en) | 2006-01-24 | 2007-08-02 | Domantis Limited | Fusion proteins that contain natural junctions |
| JP2010528647A (ja) | 2007-06-06 | 2010-08-26 | ドマンティス リミテッド | ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
| GB0724331D0 (en) * | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| MX2009013137A (es) * | 2007-06-06 | 2010-04-30 | Domantis Ltd | Metodos para seleccionar polipeptidos resistentes a la proteasa. |
| EA023031B1 (ru) | 2007-11-30 | 2016-04-29 | Глаксо Груп Лимитед | Антиген-связывающая конструкция и ее применение |
| AR075505A1 (es) * | 2009-02-19 | 2011-04-06 | Glaxo Group Ltd | Variantes de union a anti- albumina de suero mejoradas |
| PE20120170A1 (es) * | 2009-02-19 | 2012-03-21 | Glaxo Group Ltd | Variantes de union a anti-albumina de suero mejoradas |
| AU2010215479B2 (en) * | 2009-02-19 | 2015-01-22 | Glaxo Group Limited | Improved anti-TNFR1 polypeptides, antibody variable domains & antagonists |
| KR20110137819A (ko) * | 2009-03-27 | 2011-12-23 | 글락소 그룹 리미티드 | 약물 융합체 및 컨쥬게이트 |
| WO2011006914A2 (en) * | 2009-07-16 | 2011-01-20 | Glaxo Group Limited | Antagonists, uses & methods for partially inhibiting tnfr1 |
| CN102666586A (zh) * | 2009-09-30 | 2012-09-12 | 葛兰素集团有限公司 | 具有延长的半衰期的药物融合体和缀合物 |
-
2011
- 2011-05-20 KR KR1020127033268A patent/KR20130109977A/ko not_active Withdrawn
- 2011-05-20 EA EA201291009A patent/EA201291009A1/ru unknown
- 2011-05-20 MX MX2012013406A patent/MX2012013406A/es not_active Application Discontinuation
- 2011-05-20 BR BR112012029280A patent/BR112012029280A2/pt not_active IP Right Cessation
- 2011-05-20 EP EP11720310A patent/EP2571900A1/en not_active Withdrawn
- 2011-05-20 US US13/698,794 patent/US9040668B2/en not_active Expired - Fee Related
- 2011-05-20 CA CA2799633A patent/CA2799633A1/en not_active Abandoned
- 2011-05-20 WO PCT/EP2011/058298 patent/WO2011144751A1/en not_active Ceased
- 2011-05-20 JP JP2013510643A patent/JP2013529080A/ja active Pending
- 2011-05-20 AU AU2011254559A patent/AU2011254559B2/en not_active Ceased
- 2011-05-20 SG SG2012081683A patent/SG185437A1/en unknown
- 2011-05-20 CN CN2011800351661A patent/CN103003303A/zh active Pending
-
2012
- 2012-11-01 IL IL222802A patent/IL222802A0/en unknown
-
2015
- 2015-04-21 US US14/691,913 patent/US20150284454A1/en not_active Abandoned